|
Market Closed -
Nasdaq
16:00:00 2026-10-28 EDT
|
5-day change | 1st Jan Change | ||
| 17.20 USD | +2.69% |
|
+8.04% | -25.22% |
| 10-19 | Ultragenyx Pharmaceutical Enters Settlement With Navinta Over Dojolvi | MT |
| 10-14 | Ultragenyx Pharmaceutical to Sell Priority Review Voucher for $203 Million | DJ |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Diagnostic & Testing Substances Manufacturers
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1.65B | - | ||||
| 1,143B | |||||
| 647B | |||||
| 506B | |||||
| 384B | |||||
| 350B |
Select your edition
All financial news and data tailored to specific country editions
